RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Clinical trial NCT06185400 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06185400
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer ERBB2 Mutation-Related Tumors ERBB2 Gene Duplication Disitamab Vedotin

Start date: 2024-02-01
Primary completion: 2025-07-01
Enrollment: 108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.